glp-1 receptor agonist antipsychotic weight gain study New Loss Drugs in Psychiatry Treatment of Antipsychotic-Induced Weight Gain

Early biosimilar pipelines now coincide with once-weekly and dual-incretin innovations, encouraging payers to re-examine cost-effectiveness thresholds and to broaden indication coverage beyond glycemic control

We recently put together an agreement in South Carolina and now some other states, where the private insurers and Medicaid and Medicare pay for sickle cell anemia treatment. That treatment is a million dollars. It cures sickle cell anemia, but its a million dollars. If we can get a generic drug, a biosimilar, that does the exact same thing for a fraction of the cost, we can make that treatment available in every state. Right now, it is barely economic for the insurance companies because they think that maybe the long-term treatment of somebody with sickle cell anemia is going to cost more than that million dollars and it's right on the borderline. If we could cut that in half, it would be a no-brainer for every single state to adopt it. To view or add a comment, sign in Cigna Healthcare recently announced it will eliminate prescription drug rebates in many commercial health plans starting in 2027, expanding to Express Scripts clients in 2028

These strategies compared to currently available drug medications such as thiazolidinediones, sulphonylureas, and insulin, have the potential to treat diabetes without causing side effects of hypoglycemia and weight gain

She leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling